Additionally, Chekol et al. [38] demonstrate that the injection of 10 μg of 89Zr-DFO-nimotuzumab showed that the liver uptake peaked at 3 days and decreased at 7 days in EGFR positive DLD-1 tumor model. This evidence concerns the gene EGFR and neoplasm.